-- Research and development expenses for the third quarter of 2008 rose to $10.1 million, compared with $6.4 million for the third quarter of 2007, primarily due to an increase in research and development headcount, spending on the PEGPH20, insulin and dermatology clinical and pre-clinical programs, and production costs associated with the manufacturing scale-up of the rHuPH20 enzyme.
-- Selling, general and administrative expenses for the third quarter of 2008 were $3.5 million, compared with $2.8 million for the third quarter of 2007, reflecting increases in compensation expenses due to higher headcount.
-- Cash and cash equivalents totaled $72.5 million as of September 30, 2008, compared with $97.7 million as of December 31, 2007.
Halozyme management will host a conference call and webcast today to discuss these topics beginning at 1:30 p.m. PST (4:30 p.m. EST). To participate via telephone, please call 888-256-9044 for domestic callers or 706-643-5585 for international callers. The conference ID # is 71335335. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers or 706-645-9291 for international callers. The conference call will be broadcast live over the Internet at http://www.halozyme.com and the replay will be available on the company's website for 30 days.
Upcoming Corporate Presentations
Halozyme management is scheduled to present at the following investment conferences:
-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST)
-- Piper Jaffray 20th Annual health Care Conference to be held at the New York Palace Hotel in New York on Wednesday, December 3, 2008 at 3:30 p.m. EST (12:30 p.m. PST).
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved